Pharmacological and neuroethological studies of three antiepileptic drugs in the Genetic Audiogenic Seizure Hamster (GASH: Sal)

Epilepsy and Behavior

Volumn 28, Issue 3, 2013, Pages 413-425

  Barrera Bailon B ^a   Oliveira, J A C ^b   Lopez D E ^a,c   Munoz L J ^d   Garcia Cairasco, N ^b   Sancho, C ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Animal models of epilepsy; Levetiracetam; Pharmacokinetics; Phenobarbital; Seizures; Valproic acid

Indexed keywords

ETIRACETAM; KEPRA; LUMINAL; PHENOBARBITAL; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ETHOLOGY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; RAT; SEDATION; SYRIAN HAMSTER;

ANIMAL MODELS OF EPILEPSY; LEVETIRACETAM; PHARMACOKINETICS; PHENOBARBITAL; SEIZURES; VALPROIC ACID;

ACOUSTIC STIMULATION; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, REFLEX; HOMEODOMAIN PROTEINS; LOCOMOTION; MALE; MASS SPECTROMETRY; PHENOBARBITAL; PIRACETAM; TIME FACTORS; TRANSCRIPTION FACTORS; VALPROIC ACID;

EID: 84880606703     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.05.028     Document Type: Article

References (68)

1. Fisher R.S., van Emde Boas W., Blume W., Elger C., Genton P., Lee P., et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46(4):470-472.
2. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W., et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51(4):676-685.
3. Pitkanen A., Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009, 14(Suppl. 1):16-25.
4. Kaneko S., et al. Genetics of epilepsy: current status and perspectives. Neurosci Res 2002, 44(1):11-30.
5. Sgado P., Viaggi C., Pinna A., Marrone C., Vaglini F., Pontis S., et al. Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res 2011, 20(2):170-181.
6. Fuentes-Santamaria V., Alvarado J.C., Herranz A.S., García-Atarés N., López D.E. Decreased levels of GABA in the inferior colliculus of the epilepsy-prone hamster (GPG/Vall). Epilepsy Res 2008, 79(2-3):224-227.
7. Gjerstad L., Tauboll E. Epilepsy and genetics. Tidsskr Nor Laegeforen 2003, 123(19):2731-2734.
8. Steinlein O.K. Channelopathies can cause epilepsy in man. Eur J Pain 2002, 6(Suppl. A):27-34.
9. Guerrini R., Casari G., Marini C. The genetic and molecular basis of epilepsy. Trends Mol Med 2003, 9(7):300-306.
10. Gurnett C.A., Hedera P. New ideas in epilepsy genetics: novel epilepsy genes, copy number alterations, and gene regulation. Arch Neurol 2007, 64(3):324-328.
11. Baraban S.C. Emerging epilepsy models: insights from mice, flies, worms and fish. Curr Opin Neurol 2007, 20(2):164-168.
12. Schauwecker P.E. The relevance of individual genetic background and its role in animal models of epilepsy. Epilepsy Res 2011, 97(1-2):1-11.
13. Fuentes-Santamaria V., et al. Morphologic and neurochemical abnormalities in the auditory brainstem of the genetically epilepsy-prone hamster (GPG/Vall). Epilepsia 2005, 46(7):1027-1045.
14. Ross K.C., Coleman J.R. Developmental and genetic audiogenic seizure models: behavior and biological substrates. Neurosci Biobehav Rev 2000, 24(6):639-653.
15. Faingold C.L. Neuronal networks in the genetically epilepsy-prone rat. Adv Neurol 1999, 79:311-321.
16. Fuentes-Santamaria V., Alvarado J.C., Herranz A.S., García-Atarés N., López D.E. Morphologic and neurochemical alterations in the superior colliculus of the genetically epilepsy-prone hamster (GPG/Vall). Epilepsy Res 2007, 75(2-3):206-219.
17. Garcia-Cairasco N., Rossetti F., Oliveira J.A., Furtado Mde A. Neuroethological study of status epilepticus induced by systemic pilocarpine in Wistar audiogenic rats (WAR strain). Epilepsy Behav 2004, 5(4):455-463.
18. Garcia-Cairasco N., Wakamatsu H., Oliveira J.A., Gomes E.L., Del Bel E.A., Mello L.E. Neuroethological and morphological (Neo-Timm staining) correlates of limbic recruitment during the development of audiogenic kindling in seizure susceptible Wistar rats. Epilepsy Res 1996, 26(1):177-192.
19. Garcia-Cairasco N., Doretto M.C., Ramalho M.J., Antunes-Rodrigues J., Nonaka K.O. Audiogenic and audiogenic-like seizures: locus of induction and seizure severity determine postictal prolactin patterns. Pharmacol Biochem Behav 1996, 53(3):503-510.
20. Furtado M.A., Braga G.K., Oliveira J.A., Del Vecchio F., Garcia-Cairasco N. Behavioral, morphologic, and electroencephalographic evaluation of seizures induced by intrahippocampal microinjection of pilocarpine. Epilepsia 2002, 43(Suppl. 5):37-39.
21. Castro O.W., Furtado M.A., Tilelli C.Q., Fernandes A., Pajolla G.P., Garcia-Cairasco N. Comparative neuroanatomical and temporal characterization of FluoroJade-positive neurodegeneration after status epilepticus induced by systemic and intrahippocampal pilocarpine in Wistar rats. Brain Res 2011, 1374:43-55.
22. Etholm L., Arabadzisz D., Lipp H.P., Heggelund P. Seizure logging: a new approach to synchronized cable-free EEG and video recordings of seizure activity in mice. J Neurosci Methods 2010, 192(2):254-260.
23. Dal-Cól M.L.C., Terra-Bustamante V.C., Velasco T.R., Oliveira J.A., Sakamoto A.C., Garcia-Cairasco N. Neuroethology application for the study of human temporal lobe epilepsy: from basic to applied sciences. Epilepsy Behav 2006, 8(1):149-160.
24. Bertti P., Dal-Cól M.L., Wichert-Ana L., Kato M., Terra V.C., de Oliveira J.A., et al. The neurobiological substrates of behavioral manifestations during temporal lobe seizures: a neuroethological and ictal SPECT correlation study. Epilepsy Behav 2010, 17(3):344-353.
25. Picazo M.G., Benito P.J., García-Olmo D.C. Efficiency and safety of a technique for drawing blood from the hamster cranial vena cava. Lab Anim 2009, 38(6):211-216.
26. Contin M., Mohamed S., Candela C., Albani F., Riva R., Baruzzi A. Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(3-4):461-465.
27. Moriyama M., Yamashita S., Domoto H., Furuno K., Araki H, Gomita Y. Determination of plasma phenobarbital concentration by high-performance liquid chromatography in rat offspring. J Chromatogr B Biomed Sci Appl 1999, 723(1-2):301-305.
28. Tang M., Lau C.E., Falk J.L. Serum phenobarbital and barbital concentrations in rats on a limited food regimen. Pharmacol Biochem Behav 1979, 11(3):359-361.
29. Cheng H., Liu Z., Blum W., Byrd J.C., Klisovic R., Grever M.R., et al. Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 850(1-2):206-212.
30. Doheny H.C., Ratnaraj N., Whittington M.A., Jefferys J.G., Patsalos P.N. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999, 34(2-3):161-168.
31. Chapman A., Keane P.E., Meldrum B.S., Simiand J., Vernieres J.C. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982, 19(4):315-359.
32. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96(2):99-113.
33. Rossetti F., Rodrigues M.C., de Oliveira J.A., Garcia-Cairasco N. EEG wavelet analyses of the striatum-substantia nigra pars reticulata-superior colliculus circuitry: audiogenic seizures and anticonvulsant drug administration in Wistar audiogenic rats (War strain). Epilepsy Res 2006, 72(2-3):192-208.
34. Löscher W., Hönack D. Comparison of the anticonvulsant efficacy of primidone and phenobarbital during chronic treatment of amygdala-kindled rats. Eur J Pharmacol 1989, 162(2):309-322.
35. Conover W.J. Practical nonparametric statistics 1971, 1980, Wiley, New York.
36. Muñoz de la Pascua L., López D.E. Establecimiento y caracterización de una línea de hámsters sirios propensos a padecer convulsiones audiógenas 2005, [Salamanca]. L. Muñoz de la Pascua (Ed.).
37. Carballosa-González MM. Hacia un nuevo modelo de epilepsia: el hámster GASH:Sal. Instituto de Neurociencias Castilla y León (INCyL). 2008, Vol. Doctoral thesis, eds. Universidad de Salamanca: Salamanca.
38. Nef P. Key animal models for the identification and validation of drug targets. Drug Discov Ther 2001, 6(15 (Suppl.)):91-96.
39. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002, 50(1-2):105-123.
40. Silva Brum L.F., Elisabetsky E. Antiepileptogenic properties of phenobarbital: behavior and neurochemical analysis. Pharmacol Biochem Behav 2000, 67(3):411-416.
41. Salvador N., Guillén J., Peralta J.M. Biología general y mantenimiento de las especies más utilizadas. Ciencia y Tecnología del Animal de Laboratorio 2008, 95-150. Universidad de Alcalá, Sociedad Española para las Ciencias del Animal de Laboratorio (SECAL), Alcalá. J.M. Zuñiga, J.M. Orellana, J.A. Tur (Eds.).
42. Czuczwar S.J., Turski L., Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia 1982, 23(4):377-382.
43. Gilbert T.H., Corley S.M., Teskey G.C. Conventional anticonvulsant drugs in the guinea pig kindling model of partial seizures: effects of acute phenobarbital, valproate, and ethosuximide. Exp Brain Res 2002, 146(3):336-344.
44. Werner F.M., Covenas R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs. Curr Med Chem 2011, 18(32):4933-4948.
45. Gay M.H., Ryan G.P., Boisse N.R., Guarino J.J. Phenobarbital tolerance and physical dependence: chronically equivalent dosing model. Eur J Pharmacol 1983, 95(1-2):21-29.
46. Munoz-Garcia D., Del Ser T., Bermejo F., Portera A. Truncal ataxia in chronic anticonvulsant treatment. Association with drug-induced folate deficiency. J Neurol Sci 1982, 55(3):305-311.
47. Barcia J.A., Rubio P., Alós M., Serralta A., Belda V. Anticonvulsant and neurotoxic effects of intracerebroventricular injection of phenytoin, phenobarbital and carbamazepine in an amygdala-kindling model of epilepsy in the rat. Epilepsy Res 1999, 33(2-3):159-167.
48. The behavior of the laboratory rat 2005, Oxford University Press, New York. I.Q. Whishaw, B. Kolb (Eds.).
49. Neurobiology of grooming behavior 2010, Cambridge University Press, New York. A.V. Kalueff, J.L. LaPorte, C.L. Bergner (Eds.).
50. Godin Y., Heiner L., Mark J., Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem 1969, 16(3):869-873.
51. Simler S., Ciesielski L., Maitre M., Randrianarisoa H., Mandel P. Effect of sodium n-dipropylacetate on audiogenic seizures and brain-aminobutyric acid level. Biochem Pharmacol 1973, 22(14):1701-1708.
52. Kerwin R.W., Taberner P.V. The mechanism of action of sodium valproate. Gen Pharmacol 1981, 12(2):71-75.
53. Anlezark G., Horton R.W., Meldrium B.S., Sawaya C.B. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochem Pharmacol 1976, 25(4):413-417.
54. Kerwin R.W., Olpe H.R., Schmutz M. The effect of sodium-n-dipropyl acetate on gamma-aminobutyric acid-dependent inhibition in the rat cortex and substantia nigra in relation to its anticonvulsant activity. Br J Pharmacol 1980, 71(2):545-551.
55. Leviel V., Naquet R. A study of the action of valproic acid on the kindling effect. Epilepsia 1977, 18(2):229-234.
56. Meinardi H., Van Der Kleijn E., Meijer J.W., Van Rees H. Absorption and distribution of antiepileptic drugs. Epilepsia 1975, 16(2):353-365.
57. Schobben A.F.A.M. Pharmacokinetics and therapeutics in epilepsy 1979, (Dissertation), University of Nijmegen, Nijmegen the Netherlands.
58. Abbott F.S., Acheampong A.A. Quantitative structure-anticonvulsant activity relationships of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology 1988, 27(3):287-294.
59. Löscher W., Nau H., Marescaux C., Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 1984, 99(2-3):211-218.
60. Lim L.L., Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005, 11(2):135-137.
61. Gualtieri F., Manetti D., Romanelli M.N., Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002, 8(2):125-138.
62. Boido D., Farisello P., Cesca F., Ferrea E., Valtorta F., Benfenati F., et al. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam. Neuroscience 2010, 171(1):268-283.
63. Luszczki J.J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions 2009.
64. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988, 2(3):145-181.
65. Löscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998, 284(2):474-479.
66. Silver J.M., Shin C., McNamara J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann Neurol 1991, 29(4):356-363.
67. Gower A.J., Noyer M., Verloes R., Gobert J., Wülfert E ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992, 222(2-3):193-203.
68. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995, 22(3):207-213.